home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9408c.zip
/
M9480507.TXT
< prev
next >
Wrap
Text File
|
1994-08-20
|
3KB
|
53 lines
Document 0507
DOCN M9480507
TI Recognition properties of a panel of human recombinant Fab fragments to
the CD4 binding site of gp120 that show differing abilities to
neutralize human immunodeficiency virus type 1.
DT 9410
AU Roben P; Moore JP; Thali M; Sodroski J; Barbas CF 3rd; Burton DR;
Department of Immunology, Scripps Research Institute, La Jolla,;
California 92037.
SO J Virol. 1994 Aug;68(8):4821-8. Unique Identifier : AIDSLINE
MED/94309144
AB Six recombinant human Fab fragments that were derived from the same
human immunodeficiency virus type 1 (HIV-1)-infected individual and are
directed against the CD4 binding site (CD4bs) of the gp120 envelope
glycoprotein were studied. A range of neutralizing activity against the
HIV-1 (HXBc2) isolate was observed, with Fab b12 exhibiting the greatest
potency among the Fabs tested. The neutralizing potency of Fab b12 was
better than that of monoclonal whole antibodies directed against the
third variable (V3) region of gp120. To explore the basis for the
efficient neutralizing activity of b12, the recognition of a panel of
HIV-1 gp120 mutants by the six Fabs was studied. The patterns of
sensitivity to particular gp120 amino acid changes were similar for all
six Fabs to those seen for anti-CD4bs monoclonal antibodies derived from
HIV-1-infected individuals by conventional means. In addition,
recognition by Fab b12 demonstrated an atypical sensitivity to changes
in the V1 and V2 variable regions. Next, the binding of the Fabs to
monomeric gp120 and to the envelope glycoprotein complex was examined.
Neither the binding properties of the b12 Fab to monomeric gp120 nor the
ability of the Fab to compete with soluble CD4 for monomeric gp120
binding appeared to account for the greater neutralizing potency.
However, both quantitative and qualitative differences between the
binding of b12 and that of less potent Fabs to the cell surface envelope
glycoprotein complex were observed. Relative to less potently
neutralizing Fabs, Fab b12 exhibited a higher affinity for a
subpopulation of cell surface envelope glycoproteins, the conformation
of which was best approximated by the mature gp120 glycoprotein.
Apparently, subtle differences in the gp120 epitope recognized allow
some members of the group of anti-CD4bs antibodies to bind to the
functionally relevant envelope glycoprotein complex and to neutralize
virus more efficiently.
DE Animal Antibodies, Monoclonal/IMMUNOLOGY Antibody Affinity Antigenic
Determinants Antigens, CD4/*METABOLISM Binding Sites Cell Line
Cloning, Molecular Human HIV Antibodies/IMMUNOLOGY HIV Envelope
Protein gp120/GENETICS/*IMMUNOLOGY/METABOLISM HIV
Infections/*IMMUNOLOGY HIV-1/*IMMUNOLOGY IgG/IMMUNOLOGY
Immunoglobulins, Fab/*IMMUNOLOGY Mutation Neutralization Tests
Recombinant Proteins/IMMUNOLOGY Solubility Support, Non-U.S. Gov't
Support, U.S. Gov't, P.H.S. JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).